托吡酯治疗难治性癫痫的临床证据  

Clinical Evidences for Topiramate in Intractable Epilepsy Treating

作　　者：张鉥缨[1] 邹晓毅[1] 

机构地区：[1]四川大学华西医院神经内科,成都610041

出　　处：《中国循证医学杂志》2006年第2期142-145,共4页Chinese Journal of Evidence-based Medicine

摘　　要：为给临床合理用药提供最佳证据, 作者对检索Cochrane图书馆（2005年第3期）、MEDLINE（1996～2005）、中文生物医学期刊文献数据库（1996～2005）、中文科技期刊数据库（1996～2005）及中国期刊全文数据库（1996～2005）进行了检索,从符合标准的文献中筛选高质量的文献进行评估,以了解托吡酯治疗各型难治性癫痫的疗效和安全性.最终纳入系统评价、Meta分析和随机对照试验共11篇.所纳入文献均为A级证据.结果显示, 托吡酯辅助治疗各种类型的难治性癫痫,尤其是难治性部分发作性癫痫疗效肯定,耐受性良好,与传统抗癫痫药之间无相互作用,具有较大临床应用价值.其初始剂量为 200 mg/d, 长期维持剂量为400～600mg/d,不推荐使用600 mg/d以上剂量.We searched The Cochrane Library（Issue 3, 2005）, MEDLINE（1996-2005） ,CMCC（1996-2005）, VIP（1996-2005） ,CNKI（1996-2005） to summarize the available evidence of topiramate for an intractable epilepsy. After scanning all these articles, we identified 11 articles including meta-analysis, randomised controlled trials and systematic reviews to evaluate. Topiramate offered an alternative in the treament for intractable epilepsy, especially for partial epilepsy, and its efficacy was proven. Patients had good tolerance. And no intercross effects with the traditional anti-epileptic drugs were found. So topiramate had broad clinical value. The primary dosage of topiramate was 200mg/d. The sustaining dosage was 400-600mg/d. And we didn＇t recommend the dosage of more than 600mg/d.

关 键 词：托吡酯 癫痫 疗效 安全性 临床证据 

分 类 号：R742.1[医药卫生—神经病学与精神病学]